MP Biomedicals has named Todd Nelson president and CEO, replacing Milan Panic, founder and CEO, who will remain as chairman of the company.
Nelson was most recently CEO of eBioscience, which is in the process of being acquired by Affymetrix.
Prior to eBioscience, Nelson was vice president of global corporate development and strategy at Life Technologies. Before that, he was managing director and head of global life sciences corporate strategy and research at RBC Capital Markets and first vice president of global corporate strategy and economics at Merrill Lynch.
Nelson holds a PhD in molecular pathology from the University of Minnesota and an MBA from the Carlson School of Business.
Response Genetics has appointed Thomas Bologna as CEO and chairman of the board.
Kirk Calhoun, the former chairman, was elected to the newly created position of lead director of the board.
Denise McNairn, who has served as interim CEO since July, will continue to serve as vice president, general counsel, and secretary.
Bologna joins the firm from Orchid Cellmark (now part of Laboratory Corporation of America), where he was president and CEO.
Prior to that he was president, CEO, and a member of the board of Quorex Pharmaceuticals, which was sold to Pfizer; and chairman, president, and CEO of Ostex International, which was sold to Alere.